---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-021877"
form_type: "8-K"
ticker: "DYAI"
cik: "0001213809"
company_name: "DYADIC INTERNATIONAL INC"
filed_at: "2024-07-02T23:59:59+00:00"
generated_at: "2026-05-31T23:42:59.185344+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Dyadic enters recombinant albumin partnership with Proliant; $1.5M upfront milestone payments + profit share

## Summary
- Dyadic receives $1.5M upfront milestone payment and profit share from Proliant for recombinant albumin license.
- First product (recombinant human serum albumin) expected to launch in first half of 2025.
- Partnership targets ~$6B serum albumin market for cell culture, vaccine, medical device, diagnostic segments.
- Dyadic's COO states agreement demonstrates strategy to commercialize products and generate near-term revenue in Alternative Proteins.

## SEC filing metadata
- accession: 0001437749-24-021877
- form_type: 8-K
- ticker: DYAI
- cik: 0001213809
- company_name: DYADIC INTERNATIONAL INC
- filed_at: 2024-07-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213809/000143774924021877/0001437749-24-021877-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213809/000143774924021877/dyai20240627_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-021877
- JSON: https://secwatch.observer/filing/0001437749-24-021877.json
- Plain text: https://secwatch.observer/filing/0001437749-24-021877.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.